MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it refers to as “LSD neutralizer technology.” The tech is intended to stop the effects of an LSD trip while a patient is undergoing a therapy session.

The study is being conducted with the University Hospital Basel’s Liechti Lab via a phase one trial, which will evaluate the effect of ketanserin on the response to LSD after LSD administration. The project is associated with the firms LSD therapy studies referred to as Project Lucy, with the company looking to improve the therapy session with additional features to create a better patient experience.

Expected to be completed by year end, the company is effectively looking to evaluate the compound for use as an “emergency-off” switch for psychedelic assisted therapies. The tech, if successful, is ideal for when a “bad trip” occurs for the patient, or the session is not going as intended.

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

The study will work under the premise that the administration of 40mg of ketanserin one hour after taking LSD will significantly shorten and reduce the effects of LSD, when compared to LSD alone and a placebo. The compound is currently marketed as an antihypertensive agent.

Mindmed last traded at $5.31 on the NEO.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Mind Medicine CFO Quits Ahead Of Release Of 2021 Financial Results

It’s always a positive sign when a chief financial officer resigns the last business day...

Monday, March 28, 2022, 06:45:00 AM

Mindmed: Canaccord Calls Financing “Puzzling And Unusual”

This past week Mind Medicine Inc. (NEO: MMED) announced that they would be doing a...

Saturday, October 1, 2022, 01:04:00 PM

Mind Medicine Announces $10.0 Million Bought Deal At Large Discount To Share Price

Mind Medicine (NEO: MMED) this morning announced a bought deal financing with Eight Capital as...

Tuesday, May 5, 2020, 09:14:31 AM

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results....

Tuesday, November 17, 2020, 10:17:00 AM

Mind Medicine Sees CEO Sell $24.7 Million In Company Stock

It appears that uplisting to the Nasdaq is good for business. Or, at least for...

Wednesday, May 26, 2021, 10:14:37 AM